Shares of Sophiris Bio, Inc. (NASDAQ:SPHS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price objective of $6.33 for the company and are expecting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given Sophiris Bio an industry rank of 100 out of 265 based on the ratings given to its competitors.

Separately, Roth Capital reaffirmed a “buy” rating and set a $8.00 target price on shares of Sophiris Bio in a research note on Friday, November 11th.

Institutional investors have recently added to or reduced their stakes in the stock. Oxford Asset Management acquired a new position in Sophiris Bio during the fourth quarter valued at $491,000. Hudson Bay Capital Management LP acquired a new position in Sophiris Bio during the third quarter valued at $100,000. Finally, Airain ltd boosted its position in Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 31,713 shares during the period. 5.99% of the stock is currently owned by institutional investors.

Shares of Sophiris Bio (NASDAQ:SPHS) opened at 2.79 on Tuesday. The firm has a 50-day moving average of $2.84 and a 200 day moving average of $3.15. The firm’s market cap is $84.00 million. Sophiris Bio has a 12 month low of $0.80 and a 12 month high of $8.55.

“Zacks: Analysts Set $6.33 Price Target for Sophiris Bio, Inc. (SPHS)” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this piece can be viewed at

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

5 Day Chart for NASDAQ:SPHS

Get a free copy of the Zacks research report on Sophiris Bio (SPHS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.